il 15
Start with the article narrative. Use the right sidebar to jump from prose into concept context, nearby graph relationships, and source provenance.
The alarm signal that bypasses the main immune checkpoint — activating gut damage through a separate pathway that operates even without HLA-DQ2/DQ8.
IL-15 is a cytokine (immune signalling protein) produced by intestinal epithelial cells and dendritic cells. In celiac disease, it plays a specific and critical role: it activates the innate immune arm independently of the HLA-DQ2/DQ8 + CD4+ T cell pathway that drives the main adaptive response.
The Two-Pathway Model of Celiac Damage
Celiac disease involves two parallel immune pathways:
| Pathway | Trigger | Key Players | Result |
|---|---|---|---|
| Adaptive | Deamidated gliadin via HLA-DQ2/DQ8 | CD4+ T cells, anti-tTG antibodies | villous-atrophy, chronic inflammation |
| Innate | Short gliadin fragment p31–43/49 | IL-15, NK cells, IELs | Epithelial stress, early damage signal |
The innate pathway does not require HLA-DQ2/DQ8 recognition — this is why a small percentage of celiac patients lack these alleles, and why IL-15 inhibition is being studied as a therapeutic target.
IL-15 and Intraepithelial Lymphocytes
IL-15 is the primary survival and activation signal for IELs. In normal conditions, IELs are maintained at low density. In celiac disease, elevated IL-15 drives IEL proliferation and activation. In RCD type 2, IL-15 drives the transformation of normal IELs into aberrant IELs — cells that lose normal surface markers and behave like pre-malignant cells, carrying a high risk of progression to eatl.
As a Therapeutic Target
IL-15 inhibition is one of the most promising therapeutic directions specifically for refractory celiac disease:
- AMG-714 (Amgen) — an anti-IL-15 monoclonal antibody; Phase 2 trials in RCD type 2 and non-responsive celiac disease
- Rationale: blocking IL-15 could suppress aberrant IEL activation, reduce EATL risk, and potentially address both the innate and IEL-maintenance arms simultaneously
Unlike glutenases or larazotide-acetate (which target the supply of gluten reaching the immune system), IL-15 inhibition targets the immune response itself — making it more relevant for patients where dietary restriction alone has failed.
Related Concepts
cd4-t-cells | intraepithelial-lymphocytes | refractory-celiac | eatl | cytokines-celiac | gliadin | il-15-inhibitors